A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

NCT05865002 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Malignant Solid Neoplasm

Interventions

DRUG: AUR107

Sponsor

Aurigene Discovery Technologies Limited